Media headlines about Immuron (NASDAQ:IMRN) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immuron earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.9820111112199 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
IMRN has been the topic of a number of analyst reports. Zacks Investment Research downgraded Immuron from a “buy” rating to a “hold” rating in a research report on Thursday, March 22nd. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Immuron in a research report on Friday, March 9th. Finally, ValuEngine downgraded Immuron from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd.
Shares of Immuron stock opened at $9.35 on Friday. Immuron has a one year low of $4.47 and a one year high of $16.70.
Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases.
Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.